- Home
- JZXN vs APLT Comparison
JZXN vs APLT Comparison
Compare JZXN & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JZXN | APLT |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 18.0M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JZXN | APLT |
|---|---|---|
| Price | $1.83 | $0.11 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.25 |
| AVG Volume (30 Days) | 860.4K | ★ 10.6M |
| Earning Date | 03-05-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $97,465.00 | ★ $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $0.09 |
| 52 Week High | $312.80 | $1.50 |
Technical Indicators
Market Signals| Indicator | JZXN | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 28.56 |
| Support Level | $1.72 | $0.10 |
| Resistance Level | $2.05 | $0.12 |
| Average True Range (ATR) | 0.22 | 0.01 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 22.64 | 37.53 |
Price Performance
Historical ComparisonAbout JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.